Langenbeck's Archives of Surgery

, Volume 393, Issue 6, pp 901–910

Targeting angiogenesis in pancreatic cancer: rationale and pitfalls

Original Article

DOI: 10.1007/s00423-008-0280-z

Cite this article as:
Whipple, C. & Korc, M. Langenbecks Arch Surg (2008) 393: 901. doi:10.1007/s00423-008-0280-z



Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer responsible for over 20% of deaths due to gastrointestinal malignancies. PDAC is usually diagnosed at an advanced stage which, in part, helps to explain its high resistance to chemotherapy and radiotherapy. In addition, the cancer cells in PDAC have a high propensity to metastasize and to aberrantly express several key regulators of angiogenesis and invasion. Chemotherapy has only provided a modest impact on mean survival and often induces side effects. Targeting angiogenesis alone or in combination with other modalities should be investigated to determine if it may provide for increased survival.

Materials and methods

This review summarizes the alterations in PDAC that play a critical role in angiogenesis and provides an overview of current and therapeutic strategies that may be useful for targeting angiogenesis in this malignancy.


Pancreatic ductal adenocarcinoma (PDAC)AngiogenesisInvasionMetastasisAngiogenesis inhibitors

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Departments of Medicine, Pharmacology & ToxicologyDartmouth Hitchcock Medical Center and Dartmouth Medical SchoolHanoverUSA
  2. 2.Norris Cotton Comprehensive Cancer CenterDartmouth Hitchcock Medical Center and Dartmouth Medical SchoolLebanonUSA
  3. 3.Department of MedicineDartmouth Hitchcock Medical CenterLebanonUSA